zurück
Ivacaftor / tezacaftor / elexacaftor (new indication: cystic fibrosis; F508del mutation; heterozygous, and RF mutation; patients aged ≥ 6 - ≤ 11 years (in combination with ivacaftor))
Subject:
- Active Substance: Ivacaftor / texacaftor / elexacaftor
- Name: Kaftrio®
- Therapeutic area: Cystic fibrosis
- Pharmaceutical company: Vertex Pharmaceuticals (Germany) GmbH
Time table:
- Start: 15.02.2022
- Final decision by G-BA: 04.08.2022
Final decision:
- No additional benefit proved